Nanobiotix/$NBTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Nanobiotix
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.
Ticker
$NBTX
Sector
Primary listing
Employees
103
Headquarters
Website
Nanobiotix Metrics
BasicAdvanced
$1.6bn
-
-$0.59
0.55
-
Price and volume
Market cap
$1.6bn
Beta
0.55
52-week high
$41.89
52-week low
$3.15
Average daily volume
72k
Financial strength
Current ratio
1.091
Quick ratio
1.051
Long term debt to equity
-107.726
Total debt to equity
-112.826
Interest coverage (TTM)
-1.05%
Profitability
EBITDA (TTM)
-12.276
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-73.52%
Operating margin (TTM)
-33.39%
Effective tax rate (TTM)
-0.01%
Revenue per employee (TTM)
$374,520
Management effectiveness
Return on assets (TTM)
-10.06%
Return on equity (TTM)
31.91%
Valuation
Price to revenue (TTM)
41.518
Price to book
-16.23
Price to tangible book (TTM)
-16.23
Price to free cash flow (TTM)
-39.838
Free cash flow yield (TTM)
-2.51%
Free cash flow per share (TTM)
-0.831
Growth
Revenue change (TTM)
-553.25%
Earnings per share change (TTM)
-65.24%
3-year revenue growth (CAGR)
89.68%
10-year revenue growth (CAGR)
23.29%
3-year earnings per share growth (CAGR)
-32.65%
10-year earnings per share growth (CAGR)
-8.38%
What the Analysts think about Nanobiotix
Analyst ratings (Buy, Hold, Sell) for Nanobiotix stock.
Nanobiotix Financial Performance
Revenues and expenses
Nanobiotix Earnings Performance
Company profitability
Nanobiotix News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Nanobiotix stock?
Nanobiotix (NBTX) has a market cap of $1.6B as of April 29, 2026.
What is the P/E ratio for Nanobiotix stock?
The price to earnings (P/E) ratio for Nanobiotix (NBTX) stock is 0 as of April 29, 2026.
Does Nanobiotix stock pay dividends?
No, Nanobiotix (NBTX) stock does not pay dividends to its shareholders as of April 29, 2026.
When is the next Nanobiotix dividend payment date?
Nanobiotix (NBTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Nanobiotix?
Nanobiotix (NBTX) has a beta rating of 0.55. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.